Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Mauro Zaffaroni et al.|JAMA Neurology|2021Cited by 62
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)Silvia Messina, Claudio Solaro, Isabella Righini et al.|PLoS ONE|2017Cited by 58
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, G. Coniglio, Angelo Ghezzi et al.|Neurological Sciences|2022Cited by 32
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 10